Lars Sternås

3.2k total citations
55 papers, 1.6k citations indexed

About

Lars Sternås is a scholar working on Oncology, Hematology and Molecular Biology. According to data from OpenAlex, Lars Sternås has authored 55 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 29 papers in Hematology and 25 papers in Molecular Biology. Recurrent topics in Lars Sternås's work include Multiple Myeloma Research and Treatments (29 papers), Cancer Treatment and Pharmacology (15 papers) and Protein Degradation and Inhibitors (15 papers). Lars Sternås is often cited by papers focused on Multiple Myeloma Research and Treatments (29 papers), Cancer Treatment and Pharmacology (15 papers) and Protein Degradation and Inhibitors (15 papers). Lars Sternås collaborates with scholars based in United States, Spain and Greece. Lars Sternås's co-authors include F Grignani, Riccardo Dalla‐Favera, Craig W. Reynolds, Larry W. Kwak, Robin Pennington, Maurizio Bendandi, Floyd A. Benko, Elaine S. Jaffe, P L Duffey and Carol B. Kobrin and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Nature Medicine.

In The Last Decade

Lars Sternås

54 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Lars Sternås United States	17	866	653	516	278	265	55	1.6k
R. D. Gascoyne Canada	24	684 0.8×	535 0.8×	389 0.8×	925 3.3×	347 1.3×	39	1.9k
María Gomes da Silva Portugal	20	1.1k 1.2×	501 0.8×	714 1.4×	1.1k 4.1×	216 0.8×	83	2.3k
Michelle Francesco United States	12	841 1.0×	259 0.4×	1.2k 2.3×	371 1.3×	191 0.7×	16	1.9k
Robert Coupland Canada	22	683 0.8×	429 0.7×	241 0.5×	844 3.0×	329 1.2×	40	1.7k
Carla J. de Boer Netherlands	15	859 1.0×	566 0.9×	432 0.8×	420 1.5×	57 0.2×	19	1.8k
Stanley Frankel United States	13	424 0.5×	514 0.8×	196 0.4×	362 1.3×	211 0.8×	24	1.2k
Stephen E. Karp United States	14	783 0.9×	548 0.8×	559 1.1×	566 2.0×	104 0.4×	23	2.2k
Joan Somja Belgium	21	542 0.6×	452 0.7×	397 0.8×	136 0.5×	129 0.5×	56	1.5k
Barbara Bigerna Italy	23	664 0.8×	876 1.3×	661 1.3×	929 3.3×	692 2.6×	35	2.5k
Robert E. Sobol United States	20	797 0.9×	645 1.0×	535 1.0×	167 0.6×	257 1.0×	43	1.8k

Countries citing papers authored by Lars Sternås

Since Specialization

Citations

This map shows the geographic impact of Lars Sternås's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lars Sternås with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lars Sternås more than expected).

Fields of papers citing papers by Lars Sternås

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lars Sternås. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lars Sternås. The network helps show where Lars Sternås may publish in the future.

Co-authorship network of co-authors of Lars Sternås

This figure shows the co-authorship network connecting the top 25 collaborators of Lars Sternås. A scholar is included among the top collaborators of Lars Sternås based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lars Sternås. Lars Sternås is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

OGASAWARA, K., Kathryn J. Newhall, Stephen E. Maxwell, et al.. (2019). Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies. Clinical Pharmacokinetics. 59(2). 217–227. 24 indexed citations

Qian, Xiaozhong, Meletios Α. Dimopoulos, Michael Amatangelo, et al.. (2017). Correlative Analyses of Cereblon (CRBN), cMYC, IRF4, BLIMP1, and XBP1 with Clinical Outcomes in Stratus (MM-010), a Phase 3b Study of Pomalidomide (POM) + Low-Dose Dexamethasone (LoDEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 130. 3109–3109. 1 indexed citations

Li, Yan, Xiaomin Wang, Edward O’Mara, et al.. (2017). Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function. Clinical Pharmacology Advances and Applications. Volume 9. 133–145. 10 indexed citations

Siegel, David S., Katja Weisel, Meletios Α. Dimopoulos, et al.. (2016). Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leukemia & lymphoma. 57(12). 2833–2838. 21 indexed citations

Palumbo, Antonio, Philippe Moreau, Meletios Α. Dimopoulos, et al.. (2015). OUTCOMES FOR OLDER PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE STRATUS (MM-010) TRIAL, A SINGLE-ARM, PHASE 3B STUDY. Haematologica. 100. 82–83. 1 indexed citations

Dimopoulos, Meletios Α., Antonio Palumbo, Paolo Corradini, et al.. (2015). THE STRATUS (MM-010) TRIAL: A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA. Haematologica. 100. 83–83. 1 indexed citations

Weisel, Katja, Meletios Α. Dimopoulos, Antonio Palumbo, et al.. (2015). ANALYSIS OF PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN THE PHASE 3B STRATUS TRIAL (MM-010). Haematologica. 100. 89–90. 3 indexed citations

Weisel, Katja, Meletios Α. Dimopoulos, Kevin Song, et al.. (2015). Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial. Clinical Lymphoma Myeloma & Leukemia. 15(9). 519–530. 35 indexed citations

Dimopoulos, Meletios Α., Antonio Palumbo, Paolo Corradini, et al.. (2015). STRATUS(TM) (MM 010): A Single Arm, Phase 3b Study Evaluating Safety and Efficacy of Pomalidomide (POM) + Low Dose Dexamethasone (LoDEX) in Patients (Pts) With Refractory or Relapsed and Refractory Multiple Myeloma (RRMM). Clinical Lymphoma Myeloma & Leukemia. 15. e76–e77. 1 indexed citations

10.

Morgan, Gareth J., Antonio Palumbo, Sujith Dhanasiri, et al.. (2014). Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM ‐003 trial for pomalidomide plus low‐dose dexamethasone. British Journal of Haematology. 168(6). 820–823. 14 indexed citations

11.

Morgan, Gillian, Jesús F. San Miguel, Sujith Dhanasiri, et al.. (2014). Overall survival of patients with relapsed and refractory multiple myeloma: adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone vs. high-dose dexamethasone. Ghent University Academic Bibliography (Ghent University). 1 indexed citations

12.

Weisel, Katja, Meletios Α. Dimopoulos, Michèle Cavo, et al.. (2014). Pomalidomide + Low-Dose Dexamethasone in Patients with Refractory or Relapsed and Refractory Multiple Myeloma and Renal Impairment: Analysis of Patients from the Phase 3b Stratus Trial (MM-010). Blood. 124(21). 4755–4755. 9 indexed citations

13.

Tew, William P., Nicoletta Colombo, Isabelle Ray‐Coquard, et al.. (2013). Intravenous aflibercept in patients with platinum‐resistant, advanced ovarian cancer: Results of a randomized, double‐blind, phase 2, parallel‐arm study. Cancer. 120(3). 335–343. 39 indexed citations

14.

Wang‐Gillam, Andrea, William P. Tew, Jakob Dupont, et al.. (2011). A phase I study of subcutaneously administered aflibercept (VEGF trap) in a new formulation in patients with advanced solid tumors. Investigational New Drugs. 30(5). 1958–1961. 7 indexed citations

15.

Colombo, Nicoletta, Giorgia Mangili, Serafina Mammoliti, et al.. (2011). A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecologic Oncology. 125(1). 42–47. 69 indexed citations

16.

Leighl, Natasha B., Luis E. Raez, Benjamin Besse, et al.. (2010). A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung. Journal of Thoracic Oncology. 5(7). 1054–1059. 68 indexed citations

17.

Lockhart, A. Craig, Mace L. Rothenberg, Jakob Dupont, et al.. (2009). Phase I Study of Intravenous Vascular Endothelial Growth Factor Trap, Aflibercept, in Patients With Advanced Solid Tumors. Journal of Clinical Oncology. 28(2). 207–214. 183 indexed citations

18.

Colombo, N., Giorgia Mangili, Serafina Mammoliti, et al.. (2008). Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: Preliminary results of a pilot study. Journal of Clinical Oncology. 26(15_suppl). 14598–14598. 19 indexed citations

19.

Bendandi, Maurizio, Christopher D. Gocke, Carol B. Kobrin, et al.. (1999). Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma. Nature Medicine. 5(10). 1171–1177. 458 indexed citations

20.

Lombardi, Luigia, F Grignani, Lars Sternås, et al.. (1990). Mechanism of Negative Feed-back Regulation of c-myc Gene Expression in B-Cells and its Inactivation in Tumor Cells. Current topics in microbiology and immunology. 166. 293–301. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact